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Abstract
Background: Migrant farmworkers are among the highest-risk populations for latent TB infection (LTBI) in the
United States with numerous barriers to healthcare access and increased vulnerability to infectious diseases. LTBI is
usually diagnosed on the border using the tuberculin skin test (TST). QuantiFERON-TB Gold In-Tube (QFT-GIT) also
measures immune response against specific Mycobacterium tuberculosis antigens. The objective of this study is to
assess the comparability of TST and QFT-GIT to detect LTBI among migrant farmworkers on the border, as well as
to examine the effects of various demographic and clinical factors on test positivity.
Methods: Participants were recruited using mobile clinics on the San Luis US-Mexico border and tested with
QFT-GIT and TST. Demographic profiles and clinical histories were collected. Kappa coefficients assessed agreement
between TST and QFT-GIT using various assay cutoffs. Logistic regression examined factors associated with positive
TST or QFT-GIT results.
Results: Of 109 participants, 59 of 108 (55 %) were either TST (24/71, 34 %) or QFT-GIT (52/106, 50 %) positive.
Concordance between TST and QFT-GIT was fair (71 % agreement, ĸ = 0.38, 95 % CI: 0.15, 0.61). Factors associated
with LTBI positivity included smoking (OR = 1.26, 95 % CI–1.01–1.58) and diabetes/high blood sugar (OR = 0.70,
95 % CI = 0.51–0.98).
Discussion: Test concordance between the two tests was fair, with numerous discordant results observed.
Greater proportion of positives detected using QFT-GIT may help avoid LTBI under-diagnosis. Assessment of LTBI
status on the border provides evidence whether QFT-GIT should replace the TST in routine practice, as well as
identifies risk factors for LTBI among migrant populations.
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Background
Tuberculosis (TB) on the United States (US)-Mexico
border is a disease of overcrowding, poverty, social
exclusion, and lack of opportunity for human devel-
opment [1, 2]. The US border region, defined by the
La Paz Agreement as the area of land that stretches
100 km (62.5 miles) to the north and south of the
international border with Mexico [3], is medically
underserved, has higher uninsured rates, inequitable
health conditions and some of the fastest-growing
metropolitan areas [4]. The US-Mexico border states
account for 30 % of total registered TB cases in both
the US and Mexico [1, 5]. Yuma County, in which
the San Luis border region is located, has a TB inci-
dence rate 3–5 fold higher than the rest of the state
of Arizona [6]. Border populations are at an increased
risk of prolonged infectiousness, inadequate access to
TB treatment, and multi-drug-resistant tuberculosis
[7–9]. Infection with Mycobacterium tuberculosis ba-
cilli can lead to latent tuberculosis (LTBI), in which
the a patient is asymptomatic of disease [10]. Patients
with LTBI are not contagious. If the host immune
system is stressed or the patient develops an im-
munocompromised system (e.g. due to malnutrition,
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cancer, diabetes or HIV), LTBI can progress to active TB
disease, where the patient is symptomatic and contagious
[11, 12]. The overall lifetime risk of LTBI progressing to
active TB infection is estimated to be 5–10 % but can be
higher in high-risk populations such as those in the border
region [11, 13–15]. Migrant farmworkers are among the
highest-risk populations for LTBI in the US with an esti-
mated six-fold higher risk of developing active TB com-
pared to the average US worker [16]. Limited access to
healthcare and health insurance, language barriers, poor
education, long working hours, and political, social and
economic disenfranchisement have been identified as
barriers to healthcare and increased vulnerability to in-
fectious diseases [17]. For example, our previous study
along the border area states of Nuevo Leon and Tamau-
lipas, Mexico, identified rates of LTBI at 19 % (TB skin
test) and 38 % (QFT-GIT), depending on diagnostic
method [18]. However, while persons who have immi-
grated from TB-endemic regions of the world are rec-
ommended testing for LTBI, as is follow-up among
immigrants with suspected TB, no policies exist for
screening for LTBI among migrants along the border
[19, 20].
There are two main diagnostic tools to detect LTBI:
the tuberculin skin test (TST) and the interferon gamma
release assays (IGRA) such as the Quantiferon TB gold-
In-Tube (QFT-GIT). Both methods have strengths and
limitations. The TST is an old tool that has cross-reactive
or inadequate responses due to Bacillus Calmette-Guerin
(BCG) vaccination (common in Mexico), environmental
mycobacterium exposure (common in border soil sam-
ples), and compromised immune systems [15, 21–26].
Due to cross-reactivity, the TST can lead to false positive
results which strain important public health resources; this
may result in undue screening and treatment. The QFT-
GIT is an IGRA test that measures the immune response
to TB proteins in whole blood and is useful for individuals
who have received the BCG vaccination in the past, as it is
not cross-reactive like the TST (and hence more specific).
As it requires a single participant visit for the blood draw,
it is useful for those who may have a difficult time return-
ing for the TST reading [27]. Few studies have evaluated
the use of these tests in detecting LTBI in the US-Mexico
border region, and none in Southwest Arizona [28].
Additionally, studies have identified the prevalence of
LTBI in high-risk international border populations, but
few have investigated the prevalence of LTBI in migrant
populations who cross the US Mexico border for farm-
work. Others have shown the prevalence of LTBI
among migrant residents in the Baja California region
to be close to 40 % [28]. Understanding the rates of in-
fection in migrant farmworker populations will help
guide future treatment and health needs of these groups
[17], of particular importance given the more than three
million estimates migrant and seasonal workers in the
US [29].
Given this population’s large potential reservoir of
LTBI, and the lack of available information regarding
LTBI, the main objective of this work is to assess the
utility and comparability of the two LTBI screening tests,
TST and QFT-GIT, to detect LTBI among the migrant
farmworker population in the Yuma/San Luis region in
the state of Arizona in the United States. Second, we
aim to examine the effects of various demographic (e.g.




Migrant farmworkers (N = 109) were recruited and en-
rolled from March 2014 through November 2015 as they
were crossing the San Luis, Arizona, border. Farmworkers
were restricted to migrant workers, using the definition
provided by the Migratory Health Network: “principal em-
ployment in agriculture on a seasonal basis, and employed
as such within the last 24 months.” Individuals <18 years
old, with current self-reported or diagnosed active tuber-
culosis disease or HIV, or known pregnancy were ex-
cluded. All participants were recruited at an outdoor park
near the border crossing using a mobile clinic. The park is
frequented by migrant farmworkers and passed through
as one crosses the border. The study was advertised
through the distribution of flyers to farmworkers at work
in the field and in their living quarters. In addition, some
participants were randomly approached and the study
verbally explained while on their way home from work
close to the recruitment site. All participants signed an
informed consent with all study materials presented in
Spanish. The study was approved by the University of
Arizona’s Institutional Review Board. Monetary incen-
tives in the amount $10 were given to all participants
at the time of testing and an additional $5 provided at
the time of TST read. Participants were free to withdraw
from the study at any time.
Questionnaire
Socio-demographic and clinical data were derived
through individual interviews by trained public health
staff using a standardized survey. The survey included
demographic information (e.g. age, gender), TB exposure
history, assessment of current infection and disease, and
risk factors (housing conditions, crowding, co-morbidities
such as diabetes, and behavioral risk factors such as smok-
ing, excess alcoholic beverages (defined as five or more
drinks in a sitting), or drug use.) Educational information
was provided both verbally and in writing regarding LTBI
in Spanish.
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Procedures
Participants were tested for LTBI by TST and QFT-GIT
(for quantification of interferon gamma release). Trained
nursing personnel from the Yuma Health Services Dis-
trict, who were blinded to the patient’s clinical details
and TST result, performed the QFT-GIT test. Initially,
the blood was placed into 3 different tubes containing
1 ml each; the first did not contain antigens (negative
control), the second tube contained TB antigens (test)
and the third contained phytohaemaglutinin (mitogen or
positive control). Peripheral blood samples were then
processed 6 to 8 h after sampling from the patient. The
incubation time was 18–24 h at 37 °C. Interferon gamma
production (IU/mL) was determined by ELISA. The re-
sults were considered positive, negative or indeterminate
according to the criteria established in the manufac-
turer’s software (QFT Analysis Software v2.7, Qiagen).
Once the blood was removed to perform the QFT-GIT
test, the TST was performed using the Mantoux method,
using 0.1 mL (2 tuberculin units) of purified protein de-
rivative RT23 (Statens Serum Institute; Copenhagen,
Denmark) in the middle of the anterior face of the fore-
arm, with participants instructed to return to the same
location 48–72 h for evaluation by experienced clinical
staff. To read the TST, the transverse diameter of the in-
duration was measured in mm. The TST reaction was
scored as positive if the induration diameter was > 10 mm.
Individuals were considered to have a diagnosis of LTBI if
they were asymptomatic without clinical evidence of active
tuberculosis, but had a positive QFT-GIT and/or TST
positive reaction. All participants with a positive test were
referred for further follow-up to staff at the Yuma Health
Services District (either on-site or by phone call or letter),
with provision of all services offered free of charge.
Statistical analysis
Questionnaire data (as noted above) were collected and
then entered into RedCAP, a secure data collection
platform. The concordance between the QFT-GIT and
TST tests was calculated using statistical kappa (κ). Kappa
coefficients assessed agreement between TST and QFT-
GIT. Strengths of agreement were considered ‘poor’,
κ ≤ 0.20, ‘fair’, 0.20 < κ ≤ 0.40, ‘moderate’, 0.40 < κ ≤ 0.60,
‘good’, 0.60 < κ ≤ 0.80 and ‘very good’, 0.80 < κ ≤ 1.00.
Sensitivity and specificity could not be calculated, as
there is currently no gold standard for LTBI diagnosis.
We computed Spearman's correlation coefficient to
measure the association between the proportion of
positive QFT-GIT with TST reactivity. Logistic regres-
sion was used to estimate unadjusted odds ratios (OR)
to examine factors associated with positive TST and/or
QFT-GIT results. As a sensitivity analysis, we increased
the QFT-GIT assay (IU/mL) cutoff value from 0.35 to 1.0.
This did not substantially change results (see Additional
file 1 for full report of sensitivity analysis). A p-value < 0.05
was considered statistically significant. R version 3.2.3 was
used for statistical analysis.
Results
Figure 1 shows the flow diagram of the participants who
returned for TST reading and had blood drawn for
QFT-GIT. A total of 109 participants enrolled in the
study and had TST applied. Of these, 108 (99 %) com-
pleted procedures for at least one of the two tests, of
Fig. 1 Participant Flow Diagram
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whom 59 (54.6 %) had a positive test result by at least
one of the tests. Of 71 participants who returned for
TST reading, 24 (33.8 %) tested positive and 47 (66.2 %)
tested negative. Among the 106 participants who had
their blood drawn for QFT-GIT, 52 (49.1 %) tested posi-
tive and 54 (50.9 %) tested negative.
Most of the participants were male (76.9 %) at an aver-
age age of 46.8 years (Table 1). The majority of partici-
pants were working full time (61.2 %) and did not have
health insurance (67.7 %). Fifty-three participants (60.9 %)
reported excess alcohol use, 29 (33.3 %) reported being a
current or former smoker, and eight (9.3 %) reported
current or former injection drug use. Ten of 85 partici-
pants (13.3 %) with a response reported being diagnosed
with diabetes/high blood sugar. We compared characteris-
tics between participants who had TST read and those
who did not, and did not find any significant differences
(data not shown).
Among 68 participants who returned for TST reading
and had their blood drawn for QFT-GIT, 16 (23.5 %)
tested positive on both tests and 32 (47.1 %) tested
negative on both tests (Table 2). Of 44 participants who






Age: 46.8 ± 15.2 (mean ± SD)a
18–34 years 31 28.7
35–49 years 25 23.1
50–64 years 38 35.2
65–75 years 14 13.0
Educationb
None or some primary 18 18.4
Completed primary 24 24.5
Some secondary 37 37.8
Completed high school or above 19 19.4
Employment (hours/week)b
Full time (≥30) 60 61.2
Part time (<30) 20 20.4




Do not know 2 1.0
Years of farmwork: 19.2 ± 13.6 (mean ± SD)d
< 5 years. 21 22.3
5–10 year. 15 16.0
10–25 years. 28 29.8
> 25 years. 30 31.9
No. total persons per householdb
1–3 50 51
≥ 4 48 49
No. total persons sleeping in same roomb
1 32 32.7
2 42 42.9









Refuse to answer 1 1.1
Table 1 Participant Characteristics (N = 109) (Continued)
Current or former smokerf
Yes 29 33.3
No 56 64.4
Do not know 1 1.1
Refuse to answer 1 1.1






Do not know 2 2.7








Table 2 Comparison of TST and QFT-GIT results among the 68
participants who returned for TST reading and had their blood
drawn for QFT-GIT
QFT-GIT
TST Positive Negative Total
Positive 16 8 24
Negative 12 32 44
Total 28 40 68
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tested negative on TST (<10 mm), 12 (27 %) tested
positive using QFT-GIT (one of three with an indur-
ation <10 mm testing positive). Overall agreement rate
of results among participants who had TST and QFT-GIT
results was fair 70.6 % (k = 0.38, 95 % CI = 0.15–0.61,
p = 0.001). There was a trend towards an increased
proportion of positive QFT-GIT with increasing TST re-
activity (Spearman’s correlation coefficient 0.43, P < 0.001).
When participants were limited to those with a known
positive history of BCG vaccination, the results were
unchanged.
Table 3 shows associations between participant char-
acteristics and a positive result based on either test or
both TST and QFT-GIT. Among 71 participants who
returned for TST reading, current or former smokers
were more likely to have positive results using TST
compared to non-smokers (OR = 1.35, 95 % Confidence
Interval (CI) = 1.05–1.74) (Table 3). Current or former
injection drug use (OR = 1.59, 95 % CI = 1.03–2.46) was
associated with detecting a positive TST result. Partici-
pants with diabetes/high blood sugar were less likely to
have a positive TST result than participants who did
not have diabetes/high blood sugar (OR = 0.69, 95 %
CI = 0.49–0.97). No covariates were associated with a
positive QFT-GIT result among those who had their
blood drawn for QFT-GIT.
Among 108 participants who returned for TST reading
or had blood drawn for QFT-GIT, current or former
smoking was associated with an increased likelihood of a
positive result (OR = 1.26, 95 % CI = 1.01–1.58). Partici-
pants with diabetes/high blood sugar were 30 % less
likely to have either a positive TST or QFT-GIT result
than participants who did not have diabetes/high blood
sugar (OR = 0.70, 95 % CI = 0.51–0.98). Among 68 par-
ticipants who returned for TST reading and had their
blood drawn for QFT-GIT, current or former injection
drug users were more likely to have positive results
from both TST and QFT-GIT compared to participants
who were not injection drug users (OR = 1.82, 95 %
CI = 1.26–2.64) (Table 3).
We also looked at predictors of discordance between
TST and QFT-GIT results (positive TST and negative
QFT-GIT/negative TST and positive QFT-GIT). No covar-
iates were found to be associated with obtaining discord-
ant results between the two tests among participants who
completed both.
Discussion
In this study, the TST and QFT-GIT assays were evaluated
in the diagnosis of LTBI in a sample of migrant farm-
workers working on the US side of the US-Mexico border.
A higher proportion of individuals tested positive by the
QFT-GIT, with many of these individuals displaying a nega-
tive TST. Test concordance between the two tests was fair.
If we consider a positive result with either test to in-
dicate LTBI, our findings of approximately half of the
sample testing positive (55 %) is much higher than that
previously published in the general population in the
US (5 %) as well as a relatively high estimate, when
compared with existing border and migrant estimates
on the US and Mexico border regions of between 30–
40 % [18, 28, 30, 31]. Low socioeconomic status in other
US populations has previously been linked to increased
rates of TB disease transmission (and while unmeasured,
new infections) [26]. We may have also encountered a
population with higher prior exposure to TB, a greater
proportion of previously BCG-vaccinated individuals, or
differing immune competency and reactivity. The latter
factors may also explain the lower prevalence (24 %) of in-
dividuals testing positive concurrently on both tests.
The QFT-GIT test results unexpectedly demonstrated
a higher prevalence of LTBI compared with TST. While
these findings could be considered surprising in a highly
BCG-vaccinated population, they are consistent with
findings in other high-risk groups, both in our border
work in Mexico [18] and elsewhere [32, 33]. Others have
noted that IGRAs are sensitive for detecting LTBI in
various immuno-compromised populations [34, 35]. Of
those participants who tested negative on TST approxi-
mately a quarter tested positive using QFT-GIT. Individuals
unreactive to TST due to diminished immune response
may thus benefit from the QFT-GIT or other IGRA [34].
Anergy to TST may also have occurred due to malnutri-
tion, absence of infection or technical problems with the
test. It is possible that QFT-GIT results may be falsely posi-
tive if the 0.35 IU/ml cut-off is too low. However, in our
sensitivity analyses with a 1.0 IU/ml cut-off, the proportion
positive did not shift much. Given that other high-risk
populations, such as health care workers, can progress
to active TB with QFT responses as low as 0.35–0.7 IU/
ml, we elected to report primary study findings using the
lower cut-off [36].
As per the authors’ prior results from the Mexico side
of the border, we found the TST and QFT-GIT to show
a low level of overall concordance [18, 31]. Eight partici-
pants who had positive TST results (33 %) were negative
on QFT-GIT. This is similar to both empirical and
meta-analytic findingsfrom around the world, where a
high proportion of individuals with large skin test indu-
rations tested negative on QFT or a comparably low
kappa statistic was noted [32, 37–39]. We expect that
these findings represent false positive TST results, due
to either BCG or non-tuberculous mycobacteria (NTM)
cross-reactivity. Positive QFT results may also represent
cross-reactivity with NTM, though we were unable to
test this hypothesis [40].
In our study, current or former smokers, as well as
injection drug users, were more likely to have positive
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Table 3 Frequency, unadjusted odds ratios (OR) and 95 % confidence intervals (CI) for covariates associated with positive results by
TST, QFT-GIT, either TST or QFT-GIT and both TST and QFT-GIT
TST≥ 10 mm QFT-GIT positive TST≥ 10 mm or QFT-GIT positive TST ≥ 10 mm and QFT-GIT positive
(N = 71) (N = 106) (N = 108) (N = 68)
Demographic Characteristics:
Gender
Male Reference Reference Reference Reference
Female 0.99(0.76–1.28) 0.97(0.77–1.22) 0.98(0.78–1.23) 1.00(0.78–1.26)
Age
18–34 years Reference Reference Reference Reference
35–49 years 1.11(0.82–1.65) 0.77(0.59–1.00) 0.91(0.69–1.19) 0.92(0.69–1.22)
50–64 years 1.06(0.78–1.44) 1.04(0.82–1.31) 1.03(0.81–1.31) 1.05(0.80–1.39)
65–75 years 1.13(0.78–1.65) 1.10(0.80–1.52) 1.15(0.83–1.60) 1.10(0.78–1.57)
Education
None or some primary Reference Reference Reference Reference
Completed primary 1.18(0.82–1.68) 1.02(0.74–1.41) 1.05(0.77–1.45) 1.14(0.82–1.69)
Some secondary 1.09(0.79–1.50) 1.02(0.76–1.37) 1.07(0.80–1.44) 1.02(0.75–1.38)
Completed high school or above 1.12(0.75–1.67) 1.12(0.80–1.58) 1.12(0.80–1.58) 1.13(0.77–1.63)
Employment
Full time (≥30) Reference Reference Reference Reference
Part time (<30) 1.19(0.90–1.58) 0.98(0.76–1.26) 1.11(0.86–1.44) 1.00(0.78–1.29)
Unemployed/Not working 1.07(0.80–1.43) 1.19(0.90–1.58) 1.11(0.84–1.48) 1.30(0.98–1.72)
Health insurance
Yes Reference Reference Reference Reference
No 1.12(0.87–1.45) 1.06(0.85–1.32) 1.14(0.91–1.42) 1.03(0.81–1.30)
Years of farmwork
< 10 year. Reference Reference Reference Reference
10–25 years. 1.02(0.77–1.35) 0.87(0.68–1.12) 0.89(0.69–1.14) 0.99(0.76–1.29)
> 25 years. 1.11(0.84–1.46) 1.12(0.88–1.44) 1.13(0.89–1.45) 1.09(0.84–1.42)
No. total persons per household
1–3 Reference Reference Reference Reference
≥ 4 0.88(0.70–1.10) 1.06(0.87–1.30) 1.02(0.83–1.25) 0.92(0.75–1.13)
No. person sleep in same room
1 Reference Reference Reference Reference
2 0.88(0.68–1.08) 0.83(0.65–1.04) 0.89(0.70–1.13) 0.79(0.63–1.00)
≥ 3 0.79(0.57–1.08) 0.99(0.75–1.29) 0.92(0.70–1.22) 0.86(0.64–1.15)
Risk Factors:
Excess alcohol use
No Reference Reference Reference Reference
Yes 1.06(0.83–1.35) 0.88(0.71–1.10) 0.88(0.71–1.10) 1.02(0.82–1.27)
Current or former smoker
No Reference Reference Reference Reference
Yes 1.35(1.05–1.74)* 1.06(0.84–1.33) 1.26(1.01–1.58)* 1.02(0.80–1.30)
Current or former injection drug use
No Reference Reference Reference Reference
Yes 1.59(1.03–2.46)* 1.42(0.99–2.03) 1.28(0.89–1.84) 1.82(1.26–2.64)*
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TST results compared to non-users. Participants with
diabetes/high blood sugar were less likely to have a
positive TST result than participants who did not have
diabetes/high blood sugar. Similarly, current or former
smoking was associated with an increased likelihood of
getting a positive result from either TST or QFT-GIT
when receiving both tests. Participants with self-reported
diabetes/high blood sugar were less likely to have either a
positive TST or QFT-GIT result, as reported in other
studies [41].
While diabetes is associated with a three-fold risk of
progression a risk factor for development of active TB
[23], the mechanistic link between diabetes and LTBI
has not been closely examined. Diabetes suppresses the
immune system, with decreased levels observed of M. tu-
berculosis-specific antigen-stimulated IFN-γ production in
whole blood of diabetes patients with LTBI, potentially
resulting in an anergic response, as we hypothesize oc-
curred in our study [42, 43]. Current smoking has been
previously associated with LTBI, with the thought that
macrophages from smokers less competent in controlling
intracellular M. tuberculosis in comparison to never
smokers [44]. Likewise, drug use has been associated with
a higher prevalence of LTBI, likely due to a combination
of physiological effects of drug use, as well as environmen-
tal and risky behaviors [45].
Limitations of our study include the cross-sectional
nature of the results, as well as the ability to generalize
these local results to other parts of the border, where
there are diverse farmworker groups and socioeconomic
conditions. We may have recruited a biased sample of
participants differing from the broader farmworker
population with regards to factors such as education,
fear and trust. We also recognize that for some risk fac-
tors, levels of non-response were high and precluded
the ability to establish associations with high precision
or to run adjusted analyses. For example, missing BCG
vaccination status for 40 % of the sample precluded
stratification of the results by BCG status. Missing TST
reads on a large proportion of the sample prevented us
from being able to compare the broader group by TST/
QFT status. Finally, data were self-reported and morbidity
measures such as diabetes were not objectively verified.
Further studies could examine the two screening tests in a
larger, more representative sample, as well as evaluate host
factor associations with test response.
Conclusions
Our work provides comparative data between the
QFT-GIT and TST on the border, including utility of the
two tests and recommendations among the populations
studied. A higher proportion of individuals tested positive
by the QFT-GIT, with fair concordance between the two
tests. While we were unable to determine whether
QFT-GIT was a more specific test, the importance of a
test that does not cross-react with BCG vaccination is
notable in this population, with concerns regarding
both costs and adverse effects of LTBI treatment that
might occur among false positives. As per US recommen-
dations, targeted testing activities should be conducted
among groups at high risk for progression to active TB
disease (such as priority groups that are medically under-
served or immune-compromised), with intent to treat if
LTBI is detected [46]. Given the observed risk factors for
progression to active TB disease, it is important to provide
populations on the border with information around TB
and LTBI, including trainings and informational materials.
Additional research on LTBI screening among different
high-risk subpopulations on the border is also needed.
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